Research location
Schaumburg
Illinois, United States
Advertisement
Research activity in Schaumburg
Illinois, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 42 trials and 42 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Schaumburg
42 linked trials · page 1 of 1A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT07743463 · 2026-08-31 · 1 site observation
RECRUITING
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT07743450 · 2026-08-28 · 1 site observation
RECRUITING
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16 · 1 site observation
RECRUITING
Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865 · 2026-02-26 · 1 site observation
RECRUITING
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation
RECRUITING
Exactech Shoulder Post Market Clinical Follow-up StudyNCT05603728 · 2007-07-19 · 1 site observation
RECRUITING
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation
NOT_YET_RECRUITING
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026 · 2025-03-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightNCT06588296 · 2024-09-24 · 1 site observation
COMPLETED
Study of GS-0272 in Participants With Rheumatoid ArthritisNCT06031415 · 2023-09-28 · 1 site observation
TERMINATED
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisNCT05363891 · 2023-08-08 · 1 site observation
COMPLETED
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · 2023-06-15 · 1 site observation
COMPLETED
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)NCT04888585 · 2021-06-23 · 1 site observation
TERMINATED
Effects of a Red/Gold/IR LED Combination Light on Reduction of FatNCT04525573 · 2020-08-07 · 1 site observation
WITHDRAWN
A Study of Baricitinib in Participants With Rheumatoid ArthritisNCT04086745 · 2020-02-14 · 1 site observation
COMPLETED
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)NCT03919994 · 2019-03-28 · 1 site observation
COMPLETED
Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body WeightNCT02635698 · 2015-11-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's DiseaseNCT02547818 · 2015-09-15 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02442765 · 2015-07-23 · 1 site observation
COMPLETED
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive DisorderNCT02288325 · 2014-11-18 · 1 site observation
COMPLETED
Plegridy Observational ProgramNCT02230969 · 2014-11-12 · 1 site observation
COMPLETED
Genomics Used to Improve DEpression DecisionsNCT02109939 · 2014-04-01 · 1 site observation
COMPLETED
Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) ImplantNCT01993862 · 2014-03-17 · 1 site observation
COMPLETED
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of SchizophreniaNCT01939548 · 2013-10-01 · 1 site observation
TERMINATED
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)NCT01688037 · 2012-09-01 · 1 site observation
COMPLETED
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)NCT01312922 · 2011-09-01 · 1 site observation
COMPLETED
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisNCT01309737 · 2011-03-01 · 1 site observation
COMPLETED
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisNCT01163253 · 2010-09-01 · 1 site observation
TERMINATED
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01152554 · 2010-06-01 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive DisorderNCT01153347 · 2010-06-01 · 1 site observation
COMPLETED
NeuroStar TMS Therapy System: Utilization and OutcomesNCT01114477 · 2010-03-01 · 1 site observation
COMPLETED
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)NCT00891020 · 2009-05-01 · 1 site observation
COMPLETED
Proof of Concept Study of Cognitive Improvement in Patients With SchizophreniaNCT00528905 · 2007-08-01 · 1 site observation
COMPLETED
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)NCT00443443 · 2007-01-01 · 1 site observation
COMPLETED
Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To ZiprasidoneNCT00406315 · 2006-11-01 · 1 site observation
COMPLETED
Safety And Tolerability Of Ziprasidone In Adolescents With SchizophreniaNCT00265382 · 2006-06-01 · 1 site observation
TERMINATED
Safety And Efficacy Of Ziprasidone In Adolescents With SchizophreniaNCT00257192 · 2006-04-01 · 1 site observation
TERMINATED
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major DepressionNCT00128479 · 2004-09-01 · 1 site observation
COMPLETED
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective DisorderNCT00206102 · 2003-09-01 · 1 site observation
COMPLETED
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid ArthritisNCT00049751 · 2002-09-01 · 1 site observation
COMPLETED
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)NCT00418171 · 2002-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.